Atorvastatin vs Rosuvastatin for LDL and Side Effects

Atorvastatin vs Rosuvastatin Core Findings

Neither atorvastatin nor rosuvastatin is universally superior across reviewed clinical trials. At high-intensity daily doses, both drugs lower circulating LDL cholesterol by 50% or more. Rosuvastatin achieves greater percentage reductions at identical milligram amounts.

The only head-to-head outcome trial cited here, LODESTAR, randomized 4,400 Korean adults with coronary disease. That trial was open-label and found no difference in its main composite cardiovascular outcome after three years. Its recorded differences appeared in achieved LDL levels (1.8 vs 1.9 mmol/L), new diabetes needing medication, and cataract surgery.

Atorvastatin undergoes minimal renal excretion and requires no dose modification for kidney impairment. Rosuvastatin requires a 5 mg starting dose and a 10 mg daily cap in severe renal impairment. Rosuvastatin also starts at 5 mg daily in Asian patients due to higher plasma drug exposure.

Both labels say to assess LDL-C as early as 4 weeks after starting.

LDL Lowering by Dose and Intensity

Rosuvastatin delivers greater percentage reductions in low-density lipoprotein cholesterol than atorvastatin at identical milligram doses. According to the 2026 ACC/AHA dyslipidemia guideline Figure 5 and the 2018 AHA/ACC guideline Table 3, both medications provide high-intensity lipid lowering. High-intensity therapy yields an expected LDL drop of 50% or more.

High-intensity doses are atorvastatin 80 mg (or 40 mg) and rosuvastatin 20 mg (or 40 mg). Moderate-intensity regimens produce a 30% to 49% drop using atorvastatin 10 mg (or 20 mg) or rosuvastatin 10 mg (or 5 mg). These expected reductions were estimated using median LDL reductions from the VOYAGER database.

The ACC LDL-C Manager states both drugs are preferred for patients at high or very high cardiovascular risk. The 2018 guideline notes that certain Asian populations may have a greater response to certain statins. Individual patient response varies across clinical settings.

In the LIPITOR label Table 8, six-week placebo-controlled trials showed dose-dependent LDL changes. Reductions were 39% at 10 mg, 43% at 20 mg, 50% at 40 mg, and 60% at 80 mg daily. The CRESTOR label Table 10 reported six-week reductions of 45% at 5 mg, 52% at 10 mg, 55% at 20 mg, and 63% at 40 mg. These are separate placebo trials, so the LIPITOR and CRESTOR tables are not compared with each other.

In head-to-head testing in Table 11 of the CRESTOR label, rosuvastatin 10 mg lowered LDL by 46% compared to 37% for atorvastatin 10 mg. Rosuvastatin 20 mg produced a 52% reduction compared to 43% for atorvastatin 20 mg and 48% for atorvastatin 40 mg. In the open-label STELLAR trial by Jones et al. (2003) with 2,431 adults, rosuvastatin reduced LDL by a mean of 8.2% more than atorvastatin 10 to 80 mg.

STELLAR observed that 82% to 89% of patients on rosuvastatin 10 to 40 mg reached their ATP III LDL goal compared to 69% to 85% on atorvastatin 10 to 80 mg. Drug tolerability was similar across treatments in that trial. The guide on cholesterol levels by age outlines standard target thresholds.

Cardiovascular Outcomes in the LODESTAR Trial

The randomized, open-label LODESTAR trial found comparable three-year cardiovascular event rates between rosuvastatin and atorvastatin. Published by Lee et al. (BMJ, 2023), the secondary analysis evaluated 4,400 adults with coronary artery disease across 12 South Korean hospitals. Patients were enrolled from September 2016 to November 2019 using a two-by-two factorial design.

Completion was high, with 98.7% of randomized participants completing the trial. Mean daily doses at three years were 17.1 mg for rosuvastatin and 36.0 mg for atorvastatin. The three-year composite outcome of death, myocardial infarction, stroke, or coronary revascularization occurred in 8.7% on rosuvastatin and 8.2% on atorvastatin.

This difference yielded a hazard ratio of 1.06 with a 95% confidence interval of 0.86 to 1.30 and a P-value of 0.58. Mean LDL during treatment was 1.8 mmol/L on rosuvastatin and 1.9 mmol/L on atorvastatin (P<0.001). New-onset diabetes requiring antidiabetic medication arose in 7.2% of rosuvastatin patients versus 5.3% on atorvastatin (hazard ratio 1.39, 95% confidence interval 1.03 to 1.87).

Cataract surgery was performed in 2.5% of the rosuvastatin cohort compared to 1.5% in the atorvastatin cohort (hazard ratio 1.66, 95% confidence interval 1.07 to 2.58). Other recorded trial endpoints, including end-stage kidney disease and drug discontinuation due to intolerance, did not differ between arms. A post-hoc analysis by Hong et al. (2024) examined patients without diabetes at baseline taking high-intensity statins.

In that post-hoc cohort, new diabetes developed in 11.4% on rosuvastatin versus 8.8% on atorvastatin (hazard ratio 1.32, 95% confidence interval 0.98 to 1.77, P=0.071), which the authors call not significantly different. When achieved LDL fell below 70 mg/dL, diabetes rates were 13.9% versus 8.0%. In the same trial's other randomization, reported by Hong et al. (JAMA, 2023), a treat-to-target strategy (LDL 50 to 70 mg/dL) was noninferior to high-intensity treatment (rosuvastatin 20 mg or atorvastatin 40 mg). The 3-year composite rates were 8.1% versus 8.7%.

Side Effects Reported on Both Labels and in LODESTAR

Both statin labels include warnings regarding increased blood sugar, muscle symptoms, and liver enzyme elevations. The LIPITOR and CRESTOR labels both note that increases in HbA1c and fasting serum glucose have been reported with statin therapy. The CRESTOR label notes that increases may exceed the diagnostic threshold for diabetes.

In the JUPITER trial with CRESTOR 20 mg, diabetes was reported in 2.8% versus 2.3% on placebo over two years. In the SPARCL trial with LIPITOR 80 mg, diabetes occurred in 6.1% versus 3.8% on placebo. These trials enrolled distinct patient groups and cannot be directly compared.

Metabolic tracking options are detailed in the guides on the A1c test and prediabetes symptoms. Both labels cite age 65 or older, uncontrolled hypothyroidism, kidney impairment, and specific drug interactions as risk factors for myopathy and rhabdomyolysis. Higher dosages also increase muscle injury risk.

The CRESTOR label states Asian patients may face higher myopathy risks and notes increased risk at 40 mg daily compared to lower doses. The 2018 AHA/ACC guideline Table 11 notes myalgias with normal creatine kinase occur in 1% to 5% of randomized trial participants. Observational settings report myalgia frequencies of 5% to 10%.

The guideline states the large majority of patients tolerate statin rechallenge with an alternative statin or alternative dosing regimen. Skeletal muscle evaluation is covered in the creatine kinase test guide. Both medications are contraindicated in acute liver failure or decompensated cirrhosis.

Postmarketing surveillance includes rare reports of fatal and non-fatal hepatic failure for both agents. Prescribers consider liver enzyme testing prior to initiating treatment. CRESTOR clinical trials showed transaminase elevations exceeding three times the upper limit of normal in 1.1% versus 0.5% on placebo.

LIPITOR clinical trials observed persistent transaminase elevations above three times normal in approximately 0.7% of patients. Liver monitoring protocols are outlined in the liver function test guide. Regarding vision, the 2018 AHA/ACC guideline rated cataracts as an unfounded statin side effect.

However, the open-label LODESTAR trial recorded more cataract surgery in patients receiving rosuvastatin than atorvastatin (2.5% versus 1.5%).

Dose Limits for Kidney Disease, Asian Patients and Other Drugs

Atorvastatin and rosuvastatin follow distinct elimination pathways that determine kidney dosing adjustments and drug interaction profiles. The LIPITOR label states renal impairment does not affect atorvastatin plasma concentrations, so no dose adjustment is needed.

Under 2% of an administered atorvastatin dose is recovered in urine. For rosuvastatin, approximately 28% of drug clearance occurs through the kidneys following intravenous administration. The CRESTOR label requires no adjustment for mild to moderate kidney impairment.

In severe renal impairment (creatinine clearance below 30 mL/min/1.73 m² not on hemodialysis), CRESTOR must start at 5 mg and not exceed 10 mg daily. Dipstick-positive proteinuria and microscopic hematuria were more frequent with rosuvastatin 40 mg, and the label calls this generally transient and not associated with worsening kidney function.

Dose reductions can be considered for unexplained persistent proteinuria during rosuvastatin therapy. Both labels warn that renal impairment serves as a risk factor for statin-induced myopathy. Renal assessment parameters are discussed in the kidney function test guide.

For Asian patients, the CRESTOR label directs clinicians to initiate treatment at 5 mg once daily. Pharmacokinetic studies found an approximate twofold elevation in median rosuvastatin exposure among Asian individuals compared to White controls. The label says to consider risks and benefits if LDL is not controlled at doses up to 20 mg.

The LIPITOR label sections reviewed publish no ancestry-specific starting dose recommendations. Drug interactions also diverge based on distinct metabolic routes. The LIPITOR label describes atorvastatin as a CYP3A4 and drug-transporter substrate.

Concomitant use of atorvastatin with cyclosporine or gemfibrozil is not recommended on the LIPITOR label. Atorvastatin should not exceed 20 mg daily with clarithromycin, itraconazole, or specific antiviral regimens like darunavir plus ritonavir. Patients taking atorvastatin must avoid large quantities of grapefruit juice exceeding 1.2 liters daily.

Rosuvastatin is not extensively metabolized, with roughly 10% recovered as metabolites primarily via CYP2C9. The CRESTOR label advises avoiding gemfibrozil, but if unavoidable, caps dosing at 10 mg daily starting at 5 mg. With cyclosporine, rosuvastatin dosing must not exceed 5 mg daily.

Aluminum and magnesium hydroxide antacids reduce rosuvastatin absorption. Patients must take CRESTOR at least two hours before antacids. Elimination half-life is approximately 14 hours for atorvastatin and approximately 19 hours for rosuvastatin.

Triglyceride Results, Pregnancy and How Each Tablet Is Taken

Both statin labels include indications for hypertriglyceridemia and primary dysbetalipoproteinemia alongside dietary modification. In clinical trials of primary hypertriglyceridemia, the CRESTOR label showed median triglyceride reductions of 21% at 5 mg to 43% at 40 mg versus a 1% increase on placebo. In LIPITOR label Table 10, pooled trials in 64 patients with isolated hypertriglyceridemia showed median drops of 41.0% at 10 mg, 38.7% at 20 mg, and 51.8% at 80 mg versus a 12.4% drop on placebo.

In primary hyperlipidemia, LIPITOR Table 8 showed triglyceride reductions between 19% and 37%. The ACC LDL-C Manager notes statins generally produce a 10% to 30% dose-dependent triglyceride reduction in patients with elevated triglycerides. These were separate trials, and none of the sources reviewed ranks the two drugs on triglyceride lowering.

The triglycerides guide gives the healthy and high ranges, and the lipid panel guide explains the test that reports them. Both labels state that statins may cause fetal harm and should be discontinued when pregnancy is recognized. Breastfeeding is not recommended during therapy with either medication.

Both statins are formulated as oral tablets taken once daily with or without food. Atorvastatin tablets are manufactured in 10, 20, 40, and 80 mg strengths. Rosuvastatin tablets are available in 5, 10, 20, and 40 mg strengths.

Generic Drug Availability and Retail Pricing

Both atorvastatin and rosuvastatin are available as generic prescription tablets. HealthDay reported FDA approval of the first generic Lipitor in December 2011 across 10, 20, 40, and 80 mg strengths. The FDA emphasized that generic manufacturers must meet the same production and packaging quality standards as brand-name producers.

Healio reported FDA approval of the first generic rosuvastatin on April 29, 2016. Specific retail pricing was not published on pages loaded for this review.

A pharmacy can quote the current price for a given strength.

Clinical Selection Between Atorvastatin and Rosuvastatin

A prescriber chooses between the two; the label and trial facts below show where they differ. For patients needing high-intensity LDL reduction, both medications represent guideline-recommended options. Atorvastatin at 40 to 80 mg and rosuvastatin at 20 to 40 mg both achieve 50% or greater LDL reductions.

When severe kidney impairment is present, atorvastatin avoids dosage restrictions because, per the LIPITOR label, renal impairment does not affect its plasma concentrations. Rosuvastatin requires a 5 mg starting dose and a 10 mg ceiling in severe renal impairment. In patients of Asian ancestry, rosuvastatin begins at 5 mg daily due to elevated plasma drug exposure.

Atorvastatin has no ancestry-specific starting dose in reviewed label sections. People taking clarithromycin, itraconazole or certain HIV and hepatitis C antivirals face a 20 mg cap on atorvastatin, while cyclosporine and gemfibrozil require strict rosuvastatin caps.

For people with diabetes risk factors, LODESTAR recorded more new diabetes requiring medication on rosuvastatin (7.2% versus 5.3%). A summary of the 2026 ACC/AHA guidelines on Healio outlines target LDL levels: below 55 mg/dL for very high risk, below 70 mg/dL for high risk, and below 100 mg/dL for borderline-intermediate risk.

The ACC LDL-C Manager says adding ezetimibe to a statin may lower LDL an additional 20% to 25% on average. The how-to-lower-cholesterol guide covers diet changes and ezetimibe alongside statins.

Evidence That Would Alter This Comparison

Four kinds of trial would change this comparison. A blinded head-to-head outcome trial outside South Korea would show whether LODESTAR's finding of no difference in death, heart attack, stroke or revascularization holds elsewhere. A prospective trial designed to measure new diabetes would show whether the 7.2% versus 5.3% result and the post-hoc 11.4% versus 8.8% result repeat. A second trial tracking cataract surgery would show whether the 2.5% versus 1.5% difference repeats.

Direct comparisons in patients with chronic kidney disease would establish whether rosuvastatin's renal dose limits produce measurable differences in cardiovascular protection.

How to test cholesterol and lipids at home

You don't need a lab appointment to check your own cholesterol and lipids — a few at-home kits mail you a collection kit and return physician-reviewed results online within days:

YOYOVIVA YYLIP-01 5-in-1 Portable Cholesterol Test Meter Kit for Total Cholesterol, HDL, LDL, Triglycerides & TC/HDL Ratio, Easy-to-Use Home Lipid Testing Kit with 10 Test Strips, Lancets & Droppers

YOYOVIVA

View on Amazon →

Everlywell At-Home Cholesterol and Lipids Lab Test Collection Kit for Women and Men, Measures HDL, LDL and Triglycerides for Accurate Results from a CLIA-Certified Lab Within Days, for Ages 18 Plus

Everlywell

View on Amazon →

Prefer to order direct? The Everlywell Cholesterol & Lipids Test uses a CLIA-certified lab, physician-reviewed results, and prepaid return shipping.

What Makes a Good Omega-3 Supplement

What counts is the EPA + DHA content, not the total 'fish oil' number — aim for at least 1,000 mg combined EPA/DHA per serving. Triglyceride-form (rTG) fish oil absorbs better than the cheaper ethyl-ester form, and an IFOS freshness certificate tells you it isn't rancid. Algae-based versions work for vegetarians.

Triple Strength Omega 3 Fish Oil 3600 mg | EPA & DHA | Over 2100mg Omega-3 Fatty Acids | 1300mg EPA + 860mg DHA | Best Essential Fatty Acids | Premium Wild Caught & Burpless Fish Oil | 120 Ct

MAV NUTRITION

View on Amazon →

Nature Made Fish Oil Omega 3 Supplements, Omega 3 Fish Oil as Ethyl Esters 1200 mg Softgels, EPA DHA Supplement for Healthy Heart, Brain, Eye Support, One Per Day, 100 Softgels

Nature Made

View on Amazon →